Progress in the treatment of essential hypertension.
D018663:Adrenergic Agents / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors; D003000:Clonidine / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006143:Guanabenz / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000628:therapy; D008750:Methyldopa / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D018663:Adrenergic Agents; D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; D014665:Vasodilator Agents; D008750:Methyldopa; D006143:Guanabenz; D003000:Clonidine